A formulation is provided for the treatment of the adverse affects of skeletal
muscle degenerative diseases prevalent in humans in developing countries. The formulation
typically includes a first component including at least one of jasmone, a jasmonate,
jasmonic acid, oxo-phytodienoic acid, and a second component including at least
one of an antioxidant and carnitine. Additionally, soy milk may be utilized as
a delivery vehicle for the formulation for oral ingestion by a subject. The formulation
is designed to replenish energy levels in disease infected muscle cells, reinstate
calcium homeostasis within the muscle cells, and reduce the activity of oxidizing
free radical reactions typically caused by muscle degenerative diseases.
